microRNAs (miRs), including miR-142, modulate gene expression and processes implicated in vascular damage and may serve as therapeutic targets and agents, including in Type 1 diabetes (T1D). The project aimed to assess whether miR-142 levels differ between people with and without T1D, and to analyse miR-142 associations with cardiovascular (CVD) risk factors. Intracellular miRs were isolated from whole blood cell pellets using TRIzol-based methodology. In a cross-sectional study in 102 adults cellular miR-142 levels were significantly higher (on unadjusted and adjusted analyses) in 69 adults with T1D relative to 33 non-diabetic subjects: mean ± SD, 3.53 ± 3.66 vs. 1.25 ± 0.78, p < 0.0002, but were not related to HbA1c levels. Further miR-142 research, including longitudinal and intervention studies and basic science are of interest. miR-142 may be valuable in clinical practice for predicting health and as a treatment target.

microRNA (miR)，包括 miR-142，调节与血管损伤有关的基因表达和过程，并可作为治疗靶点和药物，包括1 型糖尿病 (T1D) 的治疗靶点和药物。该项目旨在评估患有和未患有 T1D 的人之间 miR-142 水平是否存在差异，并分析 miR-142 与心血管 (CVD) 危险因素的关联。使用基于 TRIzol 的方法从全血细胞沉淀中分离细胞内 miR。在一项对 102 名成人进行的横断面研究中，69 名 T1D 成人的细胞 miR-142 水平显着高于 33 名非糖尿病受试者：平均值±标准差，3.53±3.66 与 1.25±0.78，p  < 0.0002，但与 HbA1c 水平无关。进一步的 miR-142 研究，包括纵向和干预研究以及基础科学，令人感兴趣。miR-142 在临床实践中对于预测健康状况和作为治疗靶标可能有价值。